Comparative Pharmacology
Head-to-head clinical analysis: MYAMBUTOL versus SODIUM P A S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYAMBUTOL versus SODIUM P A S.
MYAMBUTOL vs SODIUM P.A.S.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits arabinosyl transferase, an enzyme involved in cell wall synthesis of mycobacteria, leading to inhibition of cell growth.
Sodium P.A.S. (para-aminosalicylate) inhibits folic acid synthesis in Mycobacterium tuberculosis by competing with para-aminobenzoic acid, thereby suppressing bacterial growth.
15-25 mg/kg orally once daily (max 2.5 g/day); usual dose 20 mg/kg/day.
4 g orally three times daily (total 12 g/day). For intravenous administration, 4 g (10 mL of 40% solution) diluted in 250 mL of 5% dextrose or normal saline infused over 2-3 hours three times daily.
None Documented
None Documented
Terminal elimination half-life: 3-4 hours in normal renal function; prolonged to 7-15 hours in renal impairment.
0.5–1 hour (normal renal function); prolonged to ≥10 hours in renal impairment (requires dose adjustment).
Renal: 50% unchanged drug; 20% as metabolite (ethambutol carboxylic acid); 15% as aldehyde intermediate; 15% unknown; fecal: <10%.
Primarily renal (80-90% as unchanged drug) via glomerular filtration and tubular secretion; biliary/fecal ≤10%.
Category C
Category C
Antitubercular Agent
Antitubercular Agent